Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
The chart shows the growth of an initial investment of $10,000 in Cencora, Inc., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Cencora, Inc. (COR) has returned -3.67% so far this year and 19.22% over the past 12 months. Looking at the last ten years, COR has achieved an annualized return of 16.56%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Cencora, Inc. (COR) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.54% | 3.21% | -15.40% | 3.54% | ||||||||
| 2025 | 12.54% | -0.06% | 9.68% | 4.89% | 0.52% | 3.29% | -4.77% | 1.08% | 7.04% | 7.83% | 9.07% | -8.46% |
| 2024 | 13.50% | 1.27% | 2.63% | -1.37% | -1.13% | 0.26% | 5.07% | -0.22% | -6.43% | 1.31% | 9.05% | -10.49% |
| 2023 | -2.50% | 1.95% | 2.88% | 9.84% | 0.93% | |||||||
| 2021 | 7.04% | -10.22% | -2.06% | 0.56% | -0.26% | 10.72% | 2.78% | 6.95% | -6.73% | 2.26% | 19.88% | -0.51% |
| 2020 | 4.54% | -11.77% | 11.12% | 7.62% | 1.81% | -3.13% | 6.42% | -5.12% | -2.96% | 0.27% | 4.62% | -0.69% |
| 2019 | 14.93% | 3.57% | 4.53% | 1.81% | 6.42% | -1.38% | -9.68% | 9.95% | 4.36% | -3.40% | -3.97% | -0.74% |
| 2018 | -5.17% | -13.28% | 7.36% | 3.51% | 2.17% | 3.92% | 1.19% | 4.42% | -4.49% | -15.53% | 3.41% | -10.94% |
| 2017 | 8.33% | 4.24% | 0.37% | 8.86% | 7.16% | -1.67% | 4.46% | 9.10% | -5.97% | -1.10% | 1.94% | 0.23% |
| 2016 | 7.40% | 1.23% | 16.36% | -7.10% | -5.59% | -5.26% | -1.39% | -4.31% | 11.77% |
The charts below present risk-adjusted performance metrics for Cencora, Inc. (COR) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of COR compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Cencora, Inc. volatility is 1.68%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 76.59B | 67.10B | 62.56B | 2.18B | 2.10B | 1.85B | 1.53B | 1.45B | 1.16B | 1.08B | 1.02B | 845.33M | 808.23M |
| Temporary Equity (USD) | - | - | - | - | - | - | - | - | 110.20M | 990.30M | 816.40M | 701.30M | - |
| Equity Attributable To Parent (USD) | 1.51B | 645.94M | 522.00M | 63.58M | 158.16M | 242.56M | 281.02M | 435.73M | 416.12M | 322.59M | 332.41M | 338.23M | 232.81M |
| Equity Attributable To Noncontrolling Interest (USD) | 239.07M | 140.80M | 144.28M | 8.90M | 55.73M | 92.08M | 137.62M | 161.36M | 210.19M | 335.75M | 355.90M | 372.54M | 387.38M |
| Equity (USD) | 1.75B | 786.74M | 666.29M | 72.48M | 213.89M | 334.63M | 418.64M | 597.09M | 626.31M | 658.34M | 688.31M | 710.77M | 620.19M |
| Redeemable Noncontrolling Interest, Common (USD) | - | - | - | - | - | - | - | - | 110.20M | - | - | - | - |
| Redeemable Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | 110.20M | 990.30M | 816.40M | 701.30M | - |
| Other Non-current Liabilities (USD) | 9.36B | 7.65B | 8.27B | - | - | - | - | - | - | - | - | - | - |
| Long-term Debt (USD) | 7.66B | 4.39B | 4.79B | 1.72B | 1.48B | 1.13B | 939.57M | 690.45M | 391.01M | 318.50M | 232.50M | - | - |
| Noncurrent Liabilities (USD) | 17.02B | 12.04B | 13.06B | - | - | - | - | - | - | - | - | - | - |
| Other Current Liabilities (USD) | 3.10B | 3.33B | 3.00B | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable (USD) | 54.72B | 50.94B | 45.84B | - | - | - | - | - | - | - | - | - | - |
| Current Liabilities (USD) | 57.82B | 54.28B | 48.83B | 2.10B | 1.89B | 1.52B | 1.11B | 854.22M | 536.24M | 417.08M | 328.19M | 134.56M | 188.04M |
| Liabilities (USD) | 74.84B | 66.31B | 61.89B | 2.10B | 1.89B | 1.52B | 1.11B | 854.22M | 536.24M | 417.08M | 328.19M | 134.56M | 188.04M |
| Other Non-current Assets (USD) | 18.04B | 13.20B | 13.19B | - | - | - | - | - | - | - | - | - | - |
| Intangible Assets (USD) | 3.77B | 4.00B | 4.43B | - | - | - | - | - | - | - | - | - | - |
| Fixed Assets (USD) | 2.54B | 2.18B | 2.14B | - | - | - | 6.41M | 5.36M | 6.16M | 7.47M | 7.35M | - | - |
| Noncurrent Assets (USD) | 24.35B | 19.38B | 19.76B | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets (USD) | 31.75B | 28.72B | 25.34B | - | - | - | - | - | - | - | - | - | - |
| Inventory (USD) | 20.49B | 19.00B | 17.45B | - | - | - | - | - | - | - | - | - | - |
| Current Assets (USD) | 52.24B | 47.72B | 42.80B | 2.18B | 2.10B | 1.85B | 1.53B | 1.45B | 1.16B | 1.08B | 1.02B | 845.33M | 808.23M |
| Assets (USD) | 76.59B | 67.10B | 62.56B | 2.18B | 2.10B | 1.85B | 1.53B | 1.45B | 1.16B | 1.08B | 1.02B | 845.33M | 808.23M |
Cencora reported Q1 fiscal year revenue of $85.93 billion, slightly missing Wall Street estimates of $86.03 billion, but beat earnings expectations with adjusted EPS of $4.08 versus consensus of $4.03. The company raised its 2026 sales growth guidance from 5%-7% to 7%-9% and increased full-year sales guidance to $343.79-$350.22 billion. However, the stock declined 6.67% following the announcement.
The global comparator drug sourcing market is projected to grow from USD 1.42 billion in 2025 to USD 2.72 billion by 2033, at a CAGR of 8.47%. Growth is driven by increasing global clinical trials, rising complexity of biologics, and growing outsourcing trends. North America leads with 44.60% market share, while Asia-Pacific is the fastest-growing region at 9.03% CAGR. Central sourcing dominates with 55.60% market share, while contract manufacturing organizations are the fastest-growing application segment.
AOP Health US announced expanded distribution of Rapiblyk™ (landiolol), an FDA-approved ultra-short-acting beta-blocker for treating rapid heart rates in critical care settings. The drug is now available through four major pharmaceutical wholesalers: Cardinal, Cencora Specialty Distribution, McKesson Corporation, and Morris & Dickson, enhancing accessibility for hospitals and health systems nationwide.
Cencora agreed to acquire a majority stake in OneOncology for $5 billion, funded through new debt financing. The transaction is expected to close by the end of fiscal 2026 second quarter and is anticipated to be earnings neutral in the first twelve months.
Iterum Therapeutics reports expanding market access for ORLYNVAH™, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.
Cencora reported strong Q3 financial results with sales increasing 8.7% to $80.66 billion, driven by growth in healthcare solutions and GLP-1 class product sales. The company raised its full-year adjusted EPS guidance and expects continued revenue growth.
The global cell and gene therapy third-party logistics market is projected to grow from $8.66 billion in 2024 to $20.98 billion by 2033, driven by technological advancements, increasing clinical studies, and personalized medicine demands.
The healthcare cold chain logistics market is projected to surpass $25 billion by 2025, driven by the increasing demand for specialized logistics solutions due to the complexity of distribution networks for biological therapies. However, the high costs associated with cold storage and transportation present challenges for the industry.
Cencora, a healthcare company, reported strong Q4 2024 earnings and announced the acquisition of Retina Consultants of America for $4.6 billion. The deal will add nearly 300 retina specialists to Cencora's portfolio, and the company also increased its dividend.
Datapro Inc., a leader in financial services technology, has announced a comprehensive brand refresh and the launch of a redesigned website. The changes are aimed at better reflecting the company's commitment to innovation, agility, and forward-thinking solutions.
